Abstract: Mitochondrial genome (mtDNA) mutations and the resultant mitochondrial respiratory abnormalities are associated with a wide variety of disorders, such as mitochondrial diseases, neurodegenerative diseases, diabetes, and cancer, as well as aging. Generation of model animals carrying mutant mtDNAs is important for understanding the pathophysiological mechanisms of the mtDNA-based diseases. We have succeeded in generating three kinds of mice with pathogenic mutant mtDNAs, named "mito-mice," by the introduction of mitochondria carrying pathogenic mutant mtDNAs into mouse zygotes and mouse embryonic stem (ES) cells. In the case of mito-mice possessing the heteroplasmic state of wild-type mtDNA and pathogenic mtDNA with a large-scale deletion (∆mtDNA, mito-mice∆), a high load of ∆mtDNA induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, male infertility, long-term memory defects, and renal failure. In this review, we summarize generation and clinical phenotypes of three types of mito-mice and we introduce several treatment trials for mitochondrial diseases using mito-mice∆.
Introduction
Mitochondria have their own genomes, mitochondrial DNA (mtDNA), and most cells in the body contain between 10 3 and 10 4 copies of mtDNA [4, 5] . Mammalian mtDNA encodes 13 polypeptides that are essential subunits of complexes I, III, IV, and V for oxidative phosphorylation on the inner mitochondrial membrane and 22 tRNAs and 2 rRNAs that are necessary for translation of these 13 polypeptides [4, 5] . The remaining mitochondrial proteins for oxidative phosphorylation, metabolic enzymes, DNA and RNA polymerases, and ribosomal proteins are all encoded by nuclear genome. In normal individuals, nearly all of the mtDNA is thought to be identical. In some cases, however, especially in mitochondrial diseases, wild-type and pathogenic mtDNAs coexist in cells and organs [45] . The accumulation of pathogenic mtDNAs having large-scale deletions or point mutations and the resultant mitochondrial respiration defects are manifest as a variety of disorders with clinical outcomes largely dependent on the magnitude and tissue distribution of the defects [45] .
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At present, pathogenic mutant mtDNA molecules are not restricted to patients with mitochondrial diseases, but extend to patients with diabetes mellitus and neurodegenerative diseases and further to aged subjects [45] . Although the pathogenicities of these mtDNA mutations were proved by cotransmission of the mutant mtDNAs and mitochondrial respiration defects to human mtDNAless cells (rho-0 cells) [3, 11, 21, 49] , there is as yet no convincing evidence to explain whether accumulation of these pathogenic mutant mtDNAs in tissues is responsible for the expressions of various clinical phenotypes. To resolve this problem, establishment of mice with a pathogenic mutant mtDNA could provide an ideal system. However, no procedures are available for generation of disease models carrying pathogenic mutant mtDNAs, although there have been many reports of generation of mice with mitochondrial disorders by disruption of nuclear DNA-coded factors related to mitochondrial function [10, 22, 23, 37, 39, 47] .
Generation of Transmitochondrial Mice, Mito-Mice
To our knowledge, no procedures are far available for introduction of mutagenized mammalian whole mtDNA into mitochondria in living cells or even into isolated mitochondria. The effective procedure to generate mouse models carrying pathogenic mutant mtDNA would be to exogenously introduce mitochondria carrying mutant mtDNA (see Fig. 1 ).
Using the cell fusion and electorofusion techniques, we have succeeded in generating three kinds of mitomice by introduction of mitochondria with pathogenic mutant mtDNA into mouse zygotes (Fig. 1B) and mouse ES cells (Fig. 1C) [16, 20, 48] . Methodologically, the most important point for successful generation of mitomice is to isolate a mitochondrial donor carrying mtDNA with pathogenic mutations from mouse cells (Fig. 1B  and 1C ). Since the mutation frequency in mtDNA is about 10 times higher than that in the nuclear genome, it has been known that somatic mutations occur and accumulate in mtDNA molecules with aging. Thus, we screened the occurrence of somatic mutations in mtDNA molecules in mouse cells by trapping the mutant mtDNAs into mouse rho-0 cells and succeeded in cloning three lines of cybrid cells carrying ∆mtDNA, mtDNA-COI, and mtDNA-ND6 (Fig. 1) [16, 20, 48] .
The ∆mtDNA contains 4,696 bp deletion with a breaking point from nt 7,759-12,454 and includes 6 tRNA and 7 structural genes (Fig. 1A) . The mouse ∆mtDNA is similar to mtDNA with a common deletion, which has been shown to be responsible for the pathogenesis of a mitochondrial encephalomyopathy, Kearns-Sayre syndrome [11, 12] . The mtDNA-COI sequence possesses a pathogenic missense T6589C (Val 412 Ala) mutation in a mitochondrially encoded cytochrome c oxidase I (mt-Co1m1: COI) gene (Fig. 1A) . In a human case, it has been reported that the same mtDNA-COI is associated with myopathy [44] . The mtDNA-ND6 sequence possesses a pathogenic missense A13997G (Pro 25 Leu) mutation in a mitochondrially encoded NADH dehydrogenase 6 (mt-Nd6: ND6) gene (Fig. 1A) . The mtDNA-ND6 was contained in an A11 mouse cancer cell line, and we have recently reported that the mtDNA-ND6 was associated with metastatic activity [18] .
Clinical Phenotypes of Mito-Mice∆,

Mito-MiceCOI, and Mito-MiceND6
Mito-mice∆ are heteroplasmic mice carrying both wild-type and ∆mtDNA ( Fig. 2A) , so the genetic variations in the mito-mice∆ are restricted to the proportions of the introduced pathogenic ∆mtDNA (Fig. 3) . Therefore, mito-mice∆ can provide direct evidence that mitochondrial respiration defects induced by the accumulation of ∆mtDNA are sufficient by themselves for expression of the clinical phenotypes observed in patients with mutated mtDNA [16, 27] .
In various tissues of mito-mice∆ with a high load of ∆mtDNA, more than 80%, a mosaic composition of cells with different cytochrome c oxidase (complex IV; COX) activity appeared. Since three of the 13 COX subunits are encoded in mtDNA, it has been well known that the absence of these subunits and/or tRNAs due to mtDNA mutations leads to COX defects in cells and tissues [11, 16, 18] . In cardiac muscle tissues carrying 88% ∆mtD-NA, for example, we observed three types of cells, COXpositive, COX-intermediate, and COX-negative cells [27] . Quantitative PCR analysis demonstrated that the COX activity in individual cardiac cells was coordi-nated with the amount of ∆mtDNA; COX-positive, COX-intermediate, and COX-negative cells carried 76, 83, and 91% ∆mtDNA, respectively [26] .
Since a threshold level of exogenous ∆mtDNA required to cause mitochondrial respiration defects in all mitochondria in single cells would be more than approximately 80%, mitochondrial respiratory function could be maintained quite normally if more than 20% wild-type mtDNA is present in single cells. Although ∆mtDNA is missing 6 trNA genes, proteins encoded by ∆mtDNA could be translated with the help of the corresponding tRNAs transcribed from wild-type mtDNA. On the other hand, in somatic cells with a proportion of wild-type mtDNA of less than 20%, mitochondrial translation may become limiting due to the lack of sufficient tRNAs transcribed solely from the wild-type mtDNA. Thus, the translation phase may be shifted from complementation to competition of the tRNAs in cells with more than 80% ∆mtDNA, leading to lack and/or defects of all 13 proteins encoded in mtDNA (Fig. 4A) .
Mito-mice with a high load of ∆mtDNA showed mitochondrial disease phenotypes due to mitochondrial respiration defects, such as low body weight, lactic acidosis, systemic ischemia, auriculoventricular block with Wenckebach periodicity, hearing loss, renal failures, and male infertility [16, 17, [26] [27] [28] [29] 41] . Lactic acidosis is one of the typical clinical phenotypes in patients with mitochondrial respiration defects, and the symptom suggests acceleration of the glycolytic pathway for producing ATP without mitochondrial respiration. Early symptoms of lactic acidosis could be detected in mito-mice∆ carrying approximately more than 50% ∆mtDNA [32] . Although it has been suggested that mtDNA mutations are associated with diabetic phenotypes in human cases [45] , mito-mice∆ showed antidiabetic phenotypes, such as low body weight, low blood glucose, and higher glucose sensitivity, due to acceleration of the glycolytic pathway for producing ATP without mitochondrial respiration [28] .
The ∆mtDNA load differed among progeny, and the 
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proportion of ∆mtDNA in cells and tissues increased with the time (Fig. 3 ) [16, 36] . In the case of mito-mice∆ carrying more than 70% ∆mtDNA at birth, the mitomice∆ showed mitochondrial respiration defects and disease phenotypes and consequently died at around 6 months after birth [16, 17, [26] [27] [28] [29] 41] . On the other hand, mito-mice carrying about 30-50% ∆mtDNA at the birth were healthy, but they expressed mitochondrial respiration defects and disease phenotypes and died by around 1.5 years after birth when the∆mtDNA load became 75-85%. Thus, mitochondrial respiration defects and the resultant clinical phenotypes were expressed only when the proportion of ∆mtDNA exceeded approximately 80%, showing the existence of threshold effects in pathogeneses of mitochondrial diseases (Fig. 3) .
Since mito-miceCOI are homoplasmic mice carrying mtDNA-COI, only COX activity is affected negatively (Fig. 4B) . Actually, the mito-miceCOI showed 20-30% loss of COX activity in various tissues, resulting in early growth retardation and mild lactic acidosis after glucose loading, but they did not show other clinical phenotypes at any time during their lives (Fig. 2B) [20] . These results indicated that mild mitochondrial respiration defects due to pathogenic mtDNA-COI did not induce serious clinical phenotypes, at least in mice. The mito-miceCOI are valuable models for understanding in vivo metabolic adaptation to escape from pathogenicities of mild mitochondrial respiration defects.
Since mito-miceND6 are homoplasmic mice carrying mtDNA-ND6, only complex I activity is affected negatively (Fig. 4B) . In mito-miceND6, complex I + III activity, electron transport activity from complexes I to III, was 20-30% decreased in various tissues [48] . Young mito-miceND6 showed mild lactic acidosis after glucose loading and looked like quite healthy (Fig. 2C) [48] . The mito-miceND6 would be useful in vivo models to examine mechanisms of mtDNA-mediated metastasis because mtDNA-ND6 is responsible for an active metastasis in cultured cancer cells [18] . We are now waiting and allowing them to age so that we can examine age-related phenotypes of the mito-miceND6.
In maintenance of mito-mouse colonies, female mitomice are used for breeding because of maternal inheritance of mtDNA. In the case of mito-mice∆, however, ∆mtDNA is inherited by progeny until at least the third pregnancy, since the amount of ∆mtDNA in eggs decreases with the aging of female mito-mice∆ [36] . In addition, it is difficult to obtain a large population of mito-mice∆ with the same ∆mtDNA load.
Male Infertility in Mito-Mice∆
Since most mice with genetic disruption of nuclear DNA-encoded proteins functional for mitochondrial biogenesis show lethal embryonic phenotypes [10, 22, 23] , the significance of energy supplied from mitochondrial respiration, such as for cell differentiation, maintenance, and regeneration, cannot be examined. On the other hand, mito-mouse∆ embryos with a low load of ∆mtDNA can escape from the lethal phenotypes [16, 27] , because these embryos do not express mitochondrial respiration defects. Mito-mice∆ that are models for mitochondrial diseases, therefore, are also useful for understanding energy-dependent checkpoints in in vivo events. One of the examples can be seen in mechanisms of mitochondria-related male infertility [29] . In mitomice∆, mitochondrial respiration defects due to accumulation of ∆mtDNA-induced oligospermia and asthe- nozoospermia. Most sperm from the infertile mito-mice had abnormalities in the mid-piece and nucleus. Testes of the infertile mito-mice∆ showed meiotic arrest at the zygotene stage and enhanced apoptosis. Possible pathophysiological mechanisms for the mitochondria-related male infertility are summarized in Fig. 5 . When large amounts of pathogenic mutant mtD-NA accumulate in testes, mitochondrial respiratory dysfunction is induced in spermatogenic cells. The reduction of energy production by the mitochondria induces meiotic arrest during spermatogenesis. In mito-mice∆ carrying large amounts of ∆mtDNA, we observed a decrease in spermatocytes at the pachytene and diplotene stages, and an increase in zygotene nuclei with partially fragmented and degenerated chromosomes, and we also observed a higher frequency of cells undergoing apoptosis in the region of the testis with spermatocytes. Thus, respiration-deficient spermatocytes could not complete meiosis, and these cells were removed by apoptosis. Since the ∆mtDNA load differs in each cell, however, spermatocytes carrying a relatively lower proportion of ∆mtDNA can complete meiosis and transformation into haploid spermatids. These spermatids could differentiate into sperm, but most sperm showed intermediate COX activity and abnormalities in the mid-piece and nucleus, suggesting abnormal sperm formation. Therefore, oligospermia and asthenozoospermia were induced by the meiotic arrest and enhanced apoptosis during spermatogenesis and the generation of sperms with mitochondrial respiration deficiency and abnormal morphologies, respectively, resulting in male infertility.
It has been reported that synapsis of homozygous chromosomes in the mammalian spermatogenic meiotic process begins at the zygotene stage through chromosome movement and attachment [6, 24] and that several factors for synaptonemal complexes of homozygous chromosomes, such as RAD51, DMC1, and cohesin, contain functional ATP binding domains [1, 30, 43] . Actually, abnormal and incomplete attachment of homozygous chromosomes occurred only in mito-mice∆ with a high load of ∆mtDNA. Our in vivo study using mito-mice∆ directly demonstrates that there is an energydependent checkpoint in the meiotic zygotene stage during mammalian spermatogenesis and that meiotic arrest due to pathogenic mtDNA-derived mitochondrial respiration defects results in male infertility. On the basis of these findings, we have proposed that some cases of human male infertility with unknown etiology might result from mitochondrial respiratory dysfunction [29] .
Abnormalities of Spatial Remote Memory in Mito-Mice∆
Dementia and ataxia are sometime found in patients with traditional mitochondrial diseases caused by accumulation of mutated mtDNAs, such as MELAS (mitochondrial encephalopathy, lactic acidosis, and strokelike episodes), MERRF (myoclonic epilepsy and ragged red fibers), KSS (Kearns-Sayre Syndrome), CPeO (chronic progressive external ophthalmoplegia), and NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) [1, 6, 13, 24, 30, 43] , and the same mutated mtDNAs have been identified in patients with dementia, ataxia, and Alzheimer's disease [31, 42] . Moreover, there appears to be a relationship between mtDNA polymorphisms and cognitive function in humans [38] . These findings suggest that mtDNAs with both pathogenic mutations and polymorphisms contribute to various cognitive disorders, thus leading to dementia and ataxia. It has been demonstrated that polymorphisms, at least, in mtDNAs are responsible for changes in mammalian cognitive function, since the exchange of mtDNAs between NZB/BINJ and CBA/H mice affected their learning and exploration processes [33]. However, there was no direct experimental evidence as to whether mtDNA with pathogenic mutations and the resultant mitochondrial respiration defects are responsible for cognitive alterations.
Since mito-mice∆ share the same nuclear genome background (C57BL/6), their genetic variations are restricted to the proportions of pathogenic ∆mtDNA. Thus, the use of mito-mice∆ could provide unambiguous evidence that pathological phenotypes exclusively observed in mito-mice∆ carrying high loads of ∆mtDNA are caused by ∆mtDNA-induced mitochondrial respiration defects. Our experiments clearly showed that loads of 50% or less ∆mtDNA did not induce mitochondrial respiration deficiencies in the brain tissues and were also not associated with behavioral abnormalities, whereas loads of more than 60% were able to induce mitochondrial respiration defects and downregulation of CaM kinase II subunit alpha in brain tissues, leading to impairment of spatial remote memory [41] .
The pathophysiological mechanisms of mitochondriarelated impairment of spatial remote memory can be considered in the following way (see Fig. 6 ). When more than 60% ∆mtDNA accumulates in the brain, mitochondrial respiration defects are induced. Reduction and depletion of the mitochondrial energy supply affects the processes of translation and/or targeting of mRNAs of alpha-CaMK II. It has been reported that CaM kinase II subunit alpha is important for the establishment of remote memory, including for cortical plasticity and consolidation of memory traces in cortical networks, and that mRNAs of alpha-CaMK II are targeted dendritically then translated at the site and then finally mature into constitutively active forms [14] . The reduced CaM kinase II subunit alpha would cause impairment of spatial remote memory in mito-mice∆.
There are several possible reasons why CaM kinase II subunit alpha was downregulated in the brain tissues of mito-mice∆ with high ∆mtDNA loads. The first is that mitochondrial energy supply is necessary for the dendritically targeted processes of mRNAs of alphaCaMK II. Many proteins, including cytoskeletal components and ion-motive ATPases, that are critical for the dendritically targeted processes of mRNAs of alphaCaMK II require ATP [14, 46] . This possibility was supported by the normal level of mRNAs of alpha-CaMK II in the mito-mice∆ carrying a high load of ∆mtDNA. The second possibility is that exogenous signals derived from other tissues carrying ∆mtDNA at high levels contribute to the reduction of CaM kinase II subunit alpha production in the brain tissues of the mito-mice∆. Systemic mitochondrial respiration deficiencies give rise to lactic acidosis, which is one of the diagnostic markers of mitochondrial diseases [45] , and the lactate can bind Ca 2+ [19] . The onset of lactic acidosis, therefore, could disturb calcium homeostasis and signaling in nerve cells, probably leading to the general reduction of CaM kinase II subunit alpha, although all vital functions that occur via calcium signaling should in fact be affected by the lactic acidosis.
On the basis of our findings, we suggest that some cases of human memory defect are caused by high loads of pathogenic mutant mtDNA and the resultant mitochondrial respiration defects [41] . We also suggest that improving mitochondrial respiration and/or location of CaM kinase II subunit alpha might be effective strategies for treating memory disorders, although there are biological differences between such disorders in humans and mice.
Treatment Experiments for Mitochondrial
Diseases Using Mito-Mice∆
Since the main reason for mitochondrial respiration defects in mitochondrial diseases is accumulation of pathogenic mutant mtDNAs, it has been considered that the most effective treatment strategy is to eliminate mu- tant mtDNA molecules preferentially or to dilute the molecules to below the threshold proportion for the expression of disease phenotypes. Effective procedures to obtain normal progeny from affected mothers would be nuclear transplantation from zygotes carrying a predominant amount of mutated mtDNA to enucleated normal zygotes. Nuclear transplantation inevitably cointroduces a small volume of cytoplasm and mitochondria, but the amount of mtDNA cointroduced with the nucleus is 6% of all mtDNA in zygotes [35] . Theoretically, nuclear transplantation would result in production of nuclear transplanted-zygotes with 6% ∆mtDNA from mito-mouse zygotes, even when the mito-mouse zygotes possess 100% ∆mtDNA. Since the maximum proportion of ∆mtDNA in mito-mouse zygotes was 78%, nuclear transplantation therapy could hold the proportion of cotransplanted ∆mtDNA at 5% or less. Therefore, nuclear transplantation was considered to be more effective than cytoplasmic transplantation for sufficient dilution of ∆mtDNA in zygotes of mito-mice. As expected, nuclear transplanted mito-mice∆ showed no clinical phenotypes over the course of their lives [35] . In the case of patients who have already contracted mitochondrial diseases, however, it is not possible to apply this nuclear transplantation therapy. In in vitro studies using human cell models carrying pathogenic mutant mtDNAs, unique concepts by which mutant mtDNA molecules are digested by a mitochondrial-targeted restriction enzyme or zinc-finger nuclease have been proposed as a treatment strategy [2, 25] . It has also been reported that ketogenic treatment is effective for heteroplasmic shift to lower levels of ∆mtDNA in human cells [34] . At present, however, mitochondrial diseases caused by mutant mtDNAs remain largely untreatable.
Lactate has largely been considered a dead-end product of glycolysis in the state of hypoxia. However, lactate is being proposed as an active metabolite both within and between cells [8] . Therefore, the regulation of lactate levels in the body and its cells needs to be in delicate balance. By contrast, it is well known that chronic overproduction of lactate occurs in cells with mitochondrial dysfunction, as well as in cancer cells [7, 15, 45] . In light of the importance of lactate in cellular, regional, and whole-body metabolisms [8] , it is possible that chronic lactic acidosis as a metabolic adaptation in mitochondrial diseases is itself pathogenic in terms of the progression of mitochondrial disease phenotypes and that the inhibition of accelerated lactate production could become a treatment strategy in patients with mitochondrial diseases. Gene therapy introducing an additional pathway for direct oxidation of lactate has resulted in improvement of disease phenotypes in Caenorhabditis elegans with disease-causing missense mutations in a nuclear-encoded subunit of complex I [9] .
So, we treated mito-mice∆ showing the onset of lactic acidosis with sodium dichloroacetate (DCA), a specific lactic acid-lowering agent [40] , to clarify the involvement of lactic acidosis in pathogenesis of mitochondrial diseases [32] . Mito-mice∆ in which the expression of lactic acidosis was suppressed by DCA showed recovery from mitochondrial respiration defects. Consequentially, improvement of mitochondrial disease phenotypes was observed in these mito-mice∆, and the life spans of the mice were extended. The DCA-treated mito-mice∆ also showed recovery of reduced CaM kinase II subunit alpha, mitochondrial replication and transcription factor (TFAM) that is an essential factor for replication, transcription, and maintenance of mtDNA, mtDNA-encoded gene products, and mtDNA contents. Our in vivo study succeeded in showing that the pathogenesis of mitochondrial diseases might be associated with a combination of the primary mitochondrial respiration defect and lactic acidosis-induced chronic deconditioning [32] .
A possible mechanism of lactic acidosis-induced chronic deconditioning in the pathogenesis of mitochondrial diseases may be as follows. Because it has been known that lactate can bind Ca 2+ [19] , overproduction of lactate would disturb the calcium signaling in various cells, thus reducing the levels of CaM kinase II subunit alpha. This reduction in CaM kinase II subunit alpha production would, in turn, negatively regulate PGC1α-mediated mitochondrial biogenesis processes (e.g., the expression of TFAM and mtDNA-encoded gene products and the control of mtDNA content). As a result, mitochondrial respiratory function would further deteriorate; this deterioration would be additional to the primary mitochondrial respiration defects induced by the mutated mtDNAs.
Future Prospects
All genes encoded by human mtDNA are required for mitochondrial respiratory function, so any pathogenic mutations in the mtDNA could induce fundamentally mitochondrial respiration defects, leading to clinical phenotypes associated with mitochondrial diseases. An important point for understanding the pathogenesis of mtDNA-based diseases is that the kinds and degrees of clinical phenotypes are different among the types of mutation. For example, individual mutations in different tRNA genes are responsible for MELAS, MERRF, and cardiomyopathy. In addition, nuclear genome backgrounds could be involved in the difference in clinical phenotypes, since most subunits for respiration complexes are encoded in the nuclear genome. To address the precise pathogeneses in mtDNA-based diseases, we have to generate not only new mito-mice carrying pathogenic mutant mtDNAs responsible for human cases, but also mito-mice with various nuclear genome backgrounds.
